Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.
Jie Xu,Anxin Wang,Xia Meng,Gulbahram Yalkun,Anding Xu,Zhiqiang Gao,Huisheng Chen,Yong Ji,Jun Xu,Deqin Geng,Runxiu Zhu,Bo Liu,Aiqin Dong,Hua Mu,Zhihong Lu,Shuya Li,Huaguang Zheng,Xia Chen,Yilong Wang,Xingquan Zhao,Yongjun Wang,Yongjun Wang,Anding Xu,Xingquan Zhao,Xia Chen,Yongjun Wang,Xia Meng,Yilong Wang,Jie Xu,Anxin Wang,Huaguang Zheng,Zhiqiang Gao,Lei Duan,Jinghua Zhang,Shuya Li,Donghua Lou,Zhiqiang Gao,Huisheng Chen,Yong Ji,Jun Xu,Deqin Geng,Runxiu Zhu,Bo Liu,Aiqin Dong,Qingcheng Liang,Hong Yang,Cunju Guo,Xin Li,Mingli He,Xiangyang Tian,Yong Cui,Junshan Zhou,Ning Wang,Lei Wang,Xinjiang Zhang,Xiaoping Gao,Liping Lu,Tong Li,Yan Cheng,Kaixiang Liu,Xiaokun Xi,Baojun Wang,Lin Sun,Shigang Zhao,Xiaofan Chu,Yajun Lian,Fuling Yan,Xiaoshan Wang,Dong Wang,Bei Shao,Jinsong Jiao,Heng Wu,Guanglai Li,Libin Guo,Yongjun Wang,Suyue Pan,Anding Xu,Heng Li,Jianhua Zhuang,Xin Li,Jun Wu,Anxin Wang,Donghua Lou,Yingting Zuo,Yijun Zhang,Xiaoli Zhang,Xiaofei Feng,Xia Meng,David Wang,Kehui Dong,Yanfang Liu,Hao Li,Dawei Chen,Qiushi Lv
DOI: https://doi.org/10.1161/strokeaha.120.031197
IF: 10.17
2021-02-18
Stroke
Abstract:Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12–1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49–3.43 versus 1.14, 0.85–1.52). When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. URL: https://www.clinicaltrials.gov . Unique identifier: NCT02430350.
peripheral vascular disease,clinical neurology